LONDON, April 5, 2017 /PRNewswire/ --
Quantum Genomics reported its yearly results, which highlighted the significantprogress the company has made towards the commercialisation of its product, QGC001, for treatment of hypertension (HT) and heart failure (HF). In 2016, the company both completed a 34-person Phase II HT trial (results expected June
(Logo: http://photos.prnewswire.com/prnh/20130417/608168 )
We have increased our valuation of Quantum Genomics to €180m or €20.60 per share from €172m or €20.51 per share. This is due to advancing our NPVs, offset by lower net cash and moving up some R&D spending. We expect to update our valuation following the release of results in June 2017 from the previously completed Phase IIa HT trial.
Click here to view the full report.
All reports published by Edison are available to download free of charge from its website
About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
Edison is authorised and regulated by the Financial Conduct Authority.
Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.
Contact details: Learn more at http://www.edisongroup.com and connect with Edison on:
LinkedIn: https://www.linkedin.com/company/edison-investment-research Twitter: http://www.twitter.com/Edison_Inv_Res YouTube: http://www.youtube.com/edisonitv
London +44-(0)20-3077-5700 280 High Holborn London, WC1V 7EE United Kingdom
SOURCE Edison Investment Research
Subscribe to our Free Newsletters!